KR101885940B1 - 암 치료에 사용하기 위한 5-플루오로-2'-데옥시우리딘의 포스포르아미데이트 유도체 - Google Patents

암 치료에 사용하기 위한 5-플루오로-2'-데옥시우리딘의 포스포르아미데이트 유도체 Download PDF

Info

Publication number
KR101885940B1
KR101885940B1 KR1020137025749A KR20137025749A KR101885940B1 KR 101885940 B1 KR101885940 B1 KR 101885940B1 KR 1020137025749 A KR1020137025749 A KR 1020137025749A KR 20137025749 A KR20137025749 A KR 20137025749A KR 101885940 B1 KR101885940 B1 KR 101885940B1
Authority
KR
South Korea
Prior art keywords
cancer
phosphate
naphthyl
fluoro
pharmaceutical composition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
KR1020137025749A
Other languages
English (en)
Korean (ko)
Other versions
KR20140023913A (ko
Inventor
크리스토퍼 맥귀간
잔 발자리니
매그달레나 슬루사르직
블랑카 곤지
파올라 무어지아니
Original Assignee
뉴카나 피엘씨
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=45841523&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=KR101885940(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from GBGB1103582.1A external-priority patent/GB201103582D0/en
Priority claimed from GBGB1105660.3A external-priority patent/GB201105660D0/en
Application filed by 뉴카나 피엘씨 filed Critical 뉴카나 피엘씨
Publication of KR20140023913A publication Critical patent/KR20140023913A/ko
Application granted granted Critical
Publication of KR101885940B1 publication Critical patent/KR101885940B1/ko
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6558—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/655—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having oxygen atoms, with or without sulfur, selenium, or tellurium atoms, as the only ring hetero atoms
    • C07F9/65515—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having oxygen atoms, with or without sulfur, selenium, or tellurium atoms, as the only ring hetero atoms the oxygen atom being part of a five-membered ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6558—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system
    • C07F9/65586—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system at least one of the hetero rings does not contain nitrogen as ring hetero atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6564—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having phosphorus atoms, with or without nitrogen, oxygen, sulfur, selenium or tellurium atoms, as ring hetero atoms
    • C07F9/6581—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having phosphorus atoms, with or without nitrogen, oxygen, sulfur, selenium or tellurium atoms, as ring hetero atoms having phosphorus and nitrogen atoms with or without oxygen or sulfur atoms, as ring hetero atoms
    • C07F9/6584—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having phosphorus atoms, with or without nitrogen, oxygen, sulfur, selenium or tellurium atoms, as ring hetero atoms having phosphorus and nitrogen atoms with or without oxygen or sulfur atoms, as ring hetero atoms having one phosphorus atom as ring hetero atom
    • C07F9/65842—Cyclic amide derivatives of acids of phosphorus, in which one nitrogen atom belongs to the ring
    • C07F9/65844—Cyclic amide derivatives of acids of phosphorus, in which one nitrogen atom belongs to the ring the phosphorus atom being part of a five-membered ring which may be condensed with another ring system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/06—Pyrimidine radicals
    • C07H19/10—Pyrimidine radicals with the saccharide radical esterified by phosphoric or polyphosphoric acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A61K31/7072—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid having two oxo groups directly attached to the pyrimidine ring, e.g. uridine, uridylic acid, thymidine, zidovudine

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Biochemistry (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
KR1020137025749A 2011-03-01 2012-02-29 암 치료에 사용하기 위한 5-플루오로-2'-데옥시우리딘의 포스포르아미데이트 유도체 Active KR101885940B1 (ko)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
GBGB1103582.1A GB201103582D0 (enExample) 2011-03-01 2011-03-01
GB1103582.1 2011-03-01
GB1105660.3 2011-04-01
GBGB1105660.3A GB201105660D0 (en) 2011-04-01 2011-04-01 Chemical compounds
PCT/GB2012/050457 WO2012117246A1 (en) 2011-03-01 2012-02-29 Phosphoramidate derivatives of 5 - fluoro - 2 ' - deoxyuridine for use in the treatment of cancer

Publications (2)

Publication Number Publication Date
KR20140023913A KR20140023913A (ko) 2014-02-27
KR101885940B1 true KR101885940B1 (ko) 2018-08-06

Family

ID=45841523

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020137025749A Active KR101885940B1 (ko) 2011-03-01 2012-02-29 암 치료에 사용하기 위한 5-플루오로-2'-데옥시우리딘의 포스포르아미데이트 유도체

Country Status (28)

Country Link
US (7) US8933053B2 (enExample)
EP (4) EP2681227B1 (enExample)
JP (1) JP5978232B2 (enExample)
KR (1) KR101885940B1 (enExample)
CN (2) CN104974206B (enExample)
AU (1) AU2012223012C1 (enExample)
BR (1) BR112013021986B1 (enExample)
CA (1) CA2828326C (enExample)
CL (1) CL2013002517A1 (enExample)
CY (2) CY1117445T1 (enExample)
DK (3) DK2681227T3 (enExample)
ES (4) ES2569185T3 (enExample)
HR (2) HRP20160346T1 (enExample)
HU (2) HUE060127T2 (enExample)
IL (1) IL228169A (enExample)
LT (1) LT3447061T (enExample)
MX (1) MX339822B (enExample)
NZ (1) NZ615270A (enExample)
PH (2) PH12013501723A1 (enExample)
PL (3) PL2681227T3 (enExample)
PT (2) PT3031812T (enExample)
RS (2) RS62721B1 (enExample)
RU (1) RU2614406C2 (enExample)
SG (1) SG192841A1 (enExample)
SI (2) SI3447061T1 (enExample)
SM (2) SMT202100715T1 (enExample)
WO (1) WO2012117246A1 (enExample)
ZA (2) ZA201306468B (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20200016864A (ko) * 2017-06-14 2020-02-17 뉴카나 피엘씨 인산염 유도체의 합성

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201016855D0 (en) 2010-10-06 2010-11-17 Nucana Biomed Ltd Chemical compounds
CA2828326C (en) 2011-03-01 2019-05-07 Nucana Biomed Limited Phosphoramidate derivatives of 5 - fluoro - 2' - deoxyuridine for use in the treatment of cancer
SI3150616T1 (sl) * 2012-11-16 2017-08-31 University College Cardiff Consultants Limited Mešanica rp/sp gemcitabin-(fenil-(benziloksi-l-alaninil))-fosfata
WO2015013352A2 (en) * 2013-07-25 2015-01-29 Patel Hasmukh B Nucleoside phosphoramidates and phosphoramidites
CN104447923B (zh) * 2013-09-23 2018-03-30 中国药科大学 2’‑脱氧‑2’‑氟‑2’‑甲基核苷衍生物及其制备方法与在制药中的用途
RU2553996C1 (ru) * 2013-11-27 2015-06-20 Андрей Александрович Иващенко Замещенные (2r,3r,5r)-3-гидрокси-(5-пиримидин-1-ил)тетрагидрофуран-2-илметил арил фосфорамидаты
SG11201608303QA (en) 2014-04-04 2016-11-29 Del Mar Pharmaceuticals Use of dianhydrogalactitol and analogs or derivatives thereof to treat non-small-cell carcinoma of the lung and ovarian cancer
WO2015181624A2 (en) * 2014-05-28 2015-12-03 Idenix Pharmaceuticals, Inc Nucleoside derivatives for the treatment of cancer
CN105153257B (zh) * 2014-06-12 2019-03-05 正大天晴药业集团股份有限公司 索非布韦的制备方法
HRP20201264T1 (hr) 2014-06-25 2021-02-05 NuCana plc Prolijekovi gemcitabina
PL225283B1 (pl) * 2014-07-24 2017-03-31 Univ Im Adama Mickiewicza W Poznaniu Pochodne 2,3’-anhydro-2’-deoksy-5-fluorourydyny o działaniu cytotoksycznym, sposób wytwarzania i zastosowanie
MX394059B (es) 2014-11-28 2025-03-24 NuCana plc Nuevos derivados de ester fosforamidato 3'-desoxiadenosina de 2' y/o 5' aminoacido como compuestos anti-cancer
HK1247829A1 (zh) 2015-03-06 2018-10-05 Atea Pharmaceuticals, Inc. 用於治疗HCV的β-D-2'-脱氧-2'Α-氟-2'-β-C-取代-2-改性N6-取代的嘌呤核苷酸
WO2016189055A1 (en) * 2015-05-27 2016-12-01 Idenix Pharmaceuticals Llc Nucleotides for the treatment of cancer
CN108431016A (zh) * 2015-11-16 2018-08-21 艾可瑞恩治疗公司 核酸前体药物
GB201522764D0 (en) 2015-12-23 2016-02-03 Nucana Biomed Ltd Formulations of phosphate derivatives
GB201609601D0 (en) * 2016-06-01 2016-07-13 Nucana Biomed Ltd Phosphoramidate compounds
GB201609600D0 (en) 2016-06-01 2016-07-13 Nucuna Biomed Ltd Cancer treatments
LU100724B1 (en) 2016-07-14 2018-07-31 Atea Pharmaceuticals Inc Beta-d-2'-deoxy-2'-alpha-fluoro-2'-beta-c-substituted-4'-fluoro-n6-substituted-6-amino-2-substituted purine nucleotides for the treatment of hepatitis c virus infection
EP3512863B1 (en) 2016-09-07 2021-12-08 ATEA Pharmaceuticals, Inc. 2'-substituted-n6-substituted purine nucleotides for rna virus treatment
MX2019005466A (es) 2016-11-13 2019-10-02 Imagine Pharma Composiciones y metodos para tratar diabetes, hipertension e hipercolesterolemia.
CA3041423A1 (en) 2016-12-23 2018-06-28 Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. Nucleoside phosphate compound and preparation method and use thereof
RU2644156C1 (ru) * 2017-02-28 2018-02-08 Александр Васильевич Иващенко Пролекарство ингибитора NS5B HCV полимеразы, способ его получения и применения
JP2020530035A (ja) * 2017-08-08 2020-10-15 スン・ヤット−セン・ユニバーシティＳｕｎ Ｙａｔ−Ｓｅｎ Ｕｎｉｖｅｒｓｉｔｙ 多剤耐性腫瘍を治療するための方法および組成物
GB201713916D0 (en) * 2017-08-30 2017-10-11 Nucana Biomed Ltd Treatment regimens
GB201715011D0 (en) * 2017-09-18 2017-11-01 Nucana Biomed Ltd Floxuridine synthesis
GB201720279D0 (en) 2017-12-05 2018-01-17 Nucana Biomed Ltd Anticancer compounds
US11597745B2 (en) 2018-03-09 2023-03-07 Japan Science And Technology Agency β-modified phosphoric acid compound precursor, β-modified phosphoric acid compound, reaction inhibitor and medicine containing the same, and method for inhibiting reaction
CN110387226A (zh) * 2018-04-20 2019-10-29 天津大学 一种用于检测肿瘤的荧光探针及用途
WO2020111279A1 (ja) * 2018-11-30 2020-06-04 国立大学法人 東京大学 カルボキシペプチダーゼ活性検出用蛍光プローブ
GB201904544D0 (en) 2019-04-01 2019-05-15 NuCana plc Anticancer compounds
CN110840907B (zh) * 2019-08-16 2022-11-25 南京医科大学 一类自由基敏感的尿嘧啶类ProTide前药及其药物用途
US10874687B1 (en) 2020-02-27 2020-12-29 Atea Pharmaceuticals, Inc. Highly active compounds against COVID-19
WO2021173713A1 (en) 2020-02-27 2021-09-02 Atea Pharmaceuticals, Inc. Highly active compounds against covid-19
WO2022047400A1 (en) * 2020-08-31 2022-03-03 Emory University 5'-substituted nucleoside monophosphates, prodrugs thereof, and uses related thereto
EP4630433A1 (en) 2022-12-07 2025-10-15 NuCana plc Synthesis of nucleoside derivative nuc-3373

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999037753A1 (en) * 1998-01-23 1999-07-29 Newbiotics, Inc. Enzyme catalyzed therapeutic agents
WO2005012327A2 (en) * 2003-07-21 2005-02-10 University College Cardiff Consultants Limited Nucleotide phosphoramidates as anticancer agents

Family Cites Families (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2802005A (en) 1957-08-06 S-eluorourace
US1002239A (en) 1902-04-11 1911-09-05 Stromberg Carlson Telephone Telephone system.
US2945038A (en) 1956-09-26 1960-07-12 Hoffmann La Roche 5-fluorocytosine and preparation thereof
US3201387A (en) 1963-09-18 1965-08-17 Heidelberger Charles 5-trifluoromethyluracil, derivatives thereof, and processes for preparing the same
US3792039A (en) 1971-12-27 1974-02-12 Miles Lab Poly 2'-fluoro-2'-deoxyuridylic acid
DD279248A1 (de) 1989-01-01 1990-05-30 Akad Wissenschaften Ddr Verfahren zur herstellung von 2',3'-didesoxythymidin-5'-diamidophosphaten
GB9505025D0 (en) * 1995-03-13 1995-05-03 Medical Res Council Chemical compounds
RU2197964C2 (ru) * 1995-04-12 2003-02-10 Дзе Проктер Энд Гэмбл Компани Фармацевтическая композиция, композиция стандартной лекарственной формы и способ лечения злокачественных новообразований, опухолей и вирусных инфекций
US7462605B2 (en) 1998-01-23 2008-12-09 Celmed Oncology (Usa), Inc. Phosphoramidate compounds and methods of use
HK1053126A1 (zh) 1999-07-22 2003-10-10 新生物生物公司 酶催化的治疗活化
DE10109657A1 (de) 2001-02-28 2002-09-05 Menarini Ricerche Spa Verfahren zur Herstellung von (E)-5-(2-Bromvinyl)-2`-desoxyuridin
WO2003000713A1 (en) 2001-06-21 2003-01-03 Glaxo Group Limited Nucleoside compounds in hcv
JP2008523082A (ja) 2004-12-09 2008-07-03 リージェンツ オブ ザ ユニバーシティ オブ ミネソタ 抗菌活性および抗癌活性を有するヌクレオチド
GB0505781D0 (en) 2005-03-21 2005-04-27 Univ Cardiff Chemical compounds
JP2009504704A (ja) 2005-08-15 2009-02-05 エフ．ホフマン−ラ ロシュ アーゲー 抗ウイルス４′−置換プロヌクレオチドホスホルアミダート
US7888330B2 (en) 2005-11-09 2011-02-15 Wayne State University Phosphoramidate derivatives of FAU
US7964580B2 (en) 2007-03-30 2011-06-21 Pharmasset, Inc. Nucleoside phosphoramidate prodrugs
TWI583692B (zh) 2009-05-20 2017-05-21 基利法瑪席特有限責任公司 核苷磷醯胺
CN101922935B (zh) 2010-07-16 2012-07-18 北京大学 一种最小互易结构干涉型全光纤陀螺仪
KR101995598B1 (ko) 2010-07-19 2019-07-02 길리애드 사이언시즈, 인코포레이티드 부분입체 이성질성으로 순수한 포스포라미데이트 전구약물의 제조 방법
EA025341B1 (ru) 2010-09-22 2016-12-30 Алиос Биофарма, Инк. Замещенные аналоги нуклеотидов
WO2012040126A1 (en) 2010-09-22 2012-03-29 Alios Biopharma, Inc. Substituted nucleotide analogs
GB201016855D0 (en) 2010-10-06 2010-11-17 Nucana Biomed Ltd Chemical compounds
WO2012048013A2 (en) 2010-10-06 2012-04-12 Inhibitex, Inc. Phosphorodiamidate derivatives of guanosine nucleoside compounds for treatment of viral injections
SI2681219T1 (sl) 2011-03-01 2016-02-29 Janssen Pharmaceutica, N.V. Derivati 6,7-dihidro-pirazolo(1,5-a)pirazin-4-ilamina uporabni kot inhibitorji beta-sekretaze (BACE)
CA2828326C (en) 2011-03-01 2019-05-07 Nucana Biomed Limited Phosphoramidate derivatives of 5 - fluoro - 2' - deoxyuridine for use in the treatment of cancer
LT3119794T (lt) 2014-06-25 2018-02-12 NuCana plc Kompozicija, apimanti gemcitabino provaistą
MX394059B (es) 2014-11-28 2025-03-24 NuCana plc Nuevos derivados de ester fosforamidato 3'-desoxiadenosina de 2' y/o 5' aminoacido como compuestos anti-cancer
CA2985540C (en) 2015-05-14 2021-08-24 NuCana plc Use of nuc-1031 in the treatment of cancer
GB201522764D0 (en) 2015-12-23 2016-02-03 Nucana Biomed Ltd Formulations of phosphate derivatives
GB201609600D0 (en) 2016-06-01 2016-07-13 Nucuna Biomed Ltd Cancer treatments
GB201709471D0 (en) 2017-06-14 2017-07-26 Nucana Biomed Ltd Diastereoselective synthesis of hosphate derivatives

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999037753A1 (en) * 1998-01-23 1999-07-29 Newbiotics, Inc. Enzyme catalyzed therapeutic agents
WO2005012327A2 (en) * 2003-07-21 2005-02-10 University College Cardiff Consultants Limited Nucleotide phosphoramidates as anticancer agents

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20200016864A (ko) * 2017-06-14 2020-02-17 뉴카나 피엘씨 인산염 유도체의 합성
KR102695300B1 (ko) 2017-06-14 2024-08-16 뉴카나 피엘씨 인산염 유도체의 합성

Also Published As

Publication number Publication date
SMT202100715T1 (it) 2022-01-10
ZA201306468B (en) 2015-04-29
ES3039965T3 (en) 2025-10-28
NZ615270A (en) 2015-09-25
AU2012223012B2 (en) 2015-06-18
KR20140023913A (ko) 2014-02-27
US9221866B2 (en) 2015-12-29
MX2013009815A (es) 2014-03-21
CY1117445T1 (el) 2017-04-26
HUE029022T2 (en) 2017-02-28
US10993957B2 (en) 2021-05-04
US9655915B2 (en) 2017-05-23
EP4023299B1 (en) 2025-08-20
CN103403013B (zh) 2016-03-16
PH12015500485B1 (en) 2017-04-10
CY1124871T1 (el) 2022-11-25
DK2681227T3 (da) 2016-02-22
US20170312302A1 (en) 2017-11-02
PL2681227T3 (pl) 2016-08-31
CN103403013A (zh) 2013-11-20
PH12013501723A1 (en) 2013-10-07
RU2013143862A (ru) 2015-04-10
SI2681227T1 (sl) 2016-04-29
HRP20211967T1 (hr) 2022-03-18
US11559542B2 (en) 2023-01-24
US11925658B2 (en) 2024-03-12
US20190201432A1 (en) 2019-07-04
EP3447061A1 (en) 2019-02-27
EP4023299A1 (en) 2022-07-06
US10022390B2 (en) 2018-07-17
CN104974206A (zh) 2015-10-14
EP2681227A1 (en) 2014-01-08
SMT201600132B (it) 2016-07-01
CA2828326C (en) 2019-05-07
SG192841A1 (en) 2013-09-30
RU2614406C2 (ru) 2017-03-28
HRP20160346T1 (hr) 2016-05-06
SI3447061T1 (sl) 2022-02-28
JP2014506913A (ja) 2014-03-20
EP3447061B1 (en) 2021-11-24
EP4023299C0 (en) 2025-08-20
HUE060127T2 (hu) 2023-02-28
HK1192758A1 (zh) 2014-08-29
PL3447061T3 (pl) 2022-01-31
PH12015500485A1 (en) 2017-04-10
BR112013021986B1 (pt) 2021-07-27
RS54776B1 (sr) 2016-10-31
ES2569185T3 (es) 2016-05-09
US20140057866A1 (en) 2014-02-27
ES2686219T3 (es) 2018-10-16
PT3447061T (pt) 2021-12-23
AU2012223012C1 (en) 2015-09-03
PL3031812T3 (pl) 2018-12-31
US20230165886A1 (en) 2023-06-01
MX339822B (es) 2016-06-13
CL2013002517A1 (es) 2014-07-25
US20160166596A1 (en) 2016-06-16
DK3447061T3 (da) 2022-01-03
IL228169A (en) 2016-07-31
PT3031812T (pt) 2018-10-18
US20150183817A1 (en) 2015-07-02
CA2828326A1 (en) 2012-09-07
EP3031812B1 (en) 2018-08-01
ES2903097T3 (es) 2022-03-31
EP3031812A1 (en) 2016-06-15
AU2012223012A1 (en) 2013-05-02
EP2681227B1 (en) 2016-02-10
BR112013021986A2 (pt) 2016-11-16
RS62721B1 (sr) 2022-01-31
DK3031812T3 (en) 2018-09-17
ZA201409013B (en) 2016-02-24
US20220023330A1 (en) 2022-01-27
WO2012117246A1 (en) 2012-09-07
CN104974206B (zh) 2019-08-23
LT3447061T (lt) 2022-01-25
US8933053B2 (en) 2015-01-13
JP5978232B2 (ja) 2016-08-24

Similar Documents

Publication Publication Date Title
KR101885940B1 (ko) 암 치료에 사용하기 위한 5-플루오로-2'-데옥시우리딘의 포스포르아미데이트 유도체
HK40069170A (en) Phosphoramidate derivatives of 5-fluoro-2'-deoxyuridine for use in the treatment of cancer
HK40001167A (en) Pharmaceutical formulation comprising a phosphoramidate derivative of 5-fluoro-2'-deoxyuridine for use in the treatment of cancer
HK40001167B (en) Pharmaceutical formulation comprising a phosphoramidate derivative of 5-fluoro-2'-deoxyuridine for use in the treatment of cancer
HK1192758B (en) Phosphoramidate derivatives of 5-fluoro-2'-deoxyuridine for use in the treatment of cancer

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

A201 Request for examination
E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

R18-X000 Changes to party contact information recorded

St.27 status event code: A-3-3-R10-R18-oth-X000

D13-X000 Search requested

St.27 status event code: A-1-2-D10-D13-srh-X000

D14-X000 Search report completed

St.27 status event code: A-1-2-D10-D14-srh-X000

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

R18-X000 Changes to party contact information recorded

St.27 status event code: A-3-3-R10-R18-oth-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

R17-X000 Change to representative recorded

St.27 status event code: A-3-3-R10-R17-oth-X000

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

St.27 status event code: A-1-2-D10-D22-exm-PE0701

GRNT Written decision to grant
PR0701 Registration of establishment

St.27 status event code: A-2-4-F10-F11-exm-PR0701

PR1002 Payment of registration fee

St.27 status event code: A-2-2-U10-U12-oth-PR1002

Fee payment year number: 1

PG1601 Publication of registration

St.27 status event code: A-4-4-Q10-Q13-nap-PG1601

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 4

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 5

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 6

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 7

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 8

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-OTH-PR1001 (AS PROVIDED BY THE NATIONAL OFFICE)

Year of fee payment: 8